# SPECIALTY GUIDELINE MANAGEMENT

## INGREZZA (valbenazine)

### POLICY

#### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication Treatment of adults with tardive dyskinesia

All other indications are considered experimental/investigational and not medically necessary.

#### **II. DOCUMENTATION**

Submission of the following information is necessary for both initial approval and continuation of therapy prior authorization reviews: Documentation of score of items 1 to 7 of the Abnormal Involuntary Movement Scale (AIMS).

#### **III. CRITERIA FOR INITIAL APPROVAL**

#### **Tardive dyskinesia**

Authorization of 6 months may be granted for treatment of tardive dyskinesia when the baseline AIMS score for items 1 to 7 is obtained.

#### IV. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for treatment of tardive dyskinesia when the member's tardive dyskinesia symptoms have improved as indicated by a decreased AIMS score (items 1 to 7) from baseline.

#### V. REFERENCES

- 1. Ingrezza [package insert]. San Diego, CA: Neurocrine Biosciences, Inc.; April 2020.
- 2. Hauser, Robert, et al. KINECT-3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. *American Journal of Psychiatry.* 2017 Mar 21: 1-9.

Ingrezza 1750-A SGM P2021.docx

© 2021 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.